Climetrics
The Climate Rating for Funds







Investment policy :

Monthly Factsheet - Equities - August 2021

The purpose of the fund is to invest in responsible companies committed to sustainable development, with a focus on themes including the energy transition, protecting natural resources, health, well-being, safety and social inclusion. The aim is to deliver financial performance while making a social and environmental impact in line with the themes of the sustainable development objectives set by the UN.

Key Figures as of 31/08/2021				
Net Asset Value of the Class R (EUR):	150,48			
Net Asset of the Class R (EUR M):	0,73			
Total Net Asset of the fund (EUR M):	115,40			
Market Capitalisation Median (€bn) :	13,15			
Number of holdings:	50			
Number of stocks:	44			
Equity exposure:	94,36%			

Cha	racteristics
ISIN Code:	LU1209226023
Ticker:	SSPESCR LX Equity
Europerformance classification:	European Equity
Renchmark ^{(1),}	Stoxx Europe 600 Net Return
Main risks:	No guarantee or capital protection Equity marke
Management Company:	OFI Lu:
Principal distributor and advisor :	OFI ASSET MANAGEMENT
Fund manager(s):	Beryl BOUVIER DI NOTA - Arnaud BAUDUIN
Legal form:	SICAV (UCITS V) under the laws of Luxembourg
Distribution policy:	Capitalisation
Currency:	EUF
Inception date / Management Chang	ge: 08/04/2015 - 13/7/2017
Recommended investment horizon:	Over 5 years
Valuation:	Dail
Subscription Cut-off:	D at 12h
Redemption Cut-off:	D at 12h
Settlement:	D+2
Subscription fees:	0% max incl. VA
Redemption fees:	0% max incl. VA
Outperformance fees:	20 % above benchmark
Ongoing charge:	1,97%
Custodian:	SOCIETE GENERALE BANK TRUST Luxembourg
Administrative agent:	SOCIETE GENERALE BANK TRUST Luxembourg





	Return & Volatility											
Since Management Change 5 years (cum.) 3 years (cum.) 1 year YTD 6 months 3							• "					
	Since Management Change		5 years	5 years (cum.) 3 years (cum.)		1 y	ear	YI	YTD 6		3 months	
	Return	Volat.	Return	Volat.	Return	Volat.	Return	Volat.	Return	Volat.	Return	Return
OFI FUND - RS ACT4 POSITIVE ECONOMY R	45,31%	18,06%	-	-	32,85%	19,88%	23,58%	15,50%	12,35%	12,85%	12,78%	5,48%
Benchmark ⁽¹⁾	35,13%	18,57%	-	-	32,41%	20,70%	31,20%	14,21%	20,08%	10,08%	18,11%	5,84%
											Source: E	uroperformance

Monthly returns														
	Jan.	Feb.	Mar.	Apr.	May	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.	Dec.	Year	Bench.
2017							-1,78%*	-0,69%	4,57%	2,29%	-0,80%	0,89%	4,43%	1,46%
2018	2,90%	-2,17%	-1,81%	1,77%	3,13%	-0,07%	-0,35%	1,39%	-1,77%	-9,22%	-4,26%	-6,31%	-16,23%	-10,77%
2019	6,06%	2,25%	1,74%	2,75%	-3,33%	4,56%	0,53%	-0,21%	1,65%	0,21%	4,41%	3,05%	25,99%	26,82%
2020	0,67%	-6,50%	-12,10%	8,40%	5,77%	5,27%	1,70%	5,03%	-0,74%	-4,85%	13,27%	2,82%	17,34%	-1,99%
2021	0,20%	-0,58%	4,68%	1,83%	0,30%	1,80%	0,72%	2,87%					12,35%	20,08%
	13/07/2017 to 3													Europerformar

(1) Benchmark: Stoxx Europe 600 Net Return

This is a non-contractual document provided for information only. This document is intended solely for unitholders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be deemed legally binding. Past performance is no guarantee of future performance and is not constant over time. Stated performance includes all fees with the exception of subscription and redemption fees. Investors in this fund a reexposed to nisks associated with changes or shares the Fund arising from market fluctuations. As such, the value of an interest new formal contractual in nature. The investors may consequently loss some or all of their initial investors may consequently loss some or all of their initial investment. This document is provided for information purposes only and is not intended to be either legally binding or contractual in nature. The investment cappy of the prospectus flee document is provided for information in the subscription and is not intended to be either legally binding or contractual in nature. The investment cappy of the prospectus flee document is provided for information in the subscription and is not intended to be either legally binding. Past performance is no guarantee of future value of in the investment is not constant to return a return and is not intended to be either legally binding. Past performance is not guarantee of future value of in the investment is not investment and is not intended to be either legally binding. Past performance is not guarantee of future value of in the investment is not investment shall be deemed legally binding. Past performance is not guarantee of future value in the future value of investment is not investment and is not intended to be either begally binding. Past performance in the future value of investment is not on the future value of investment value of i





Monthly Factsheet - Equities - August 2021





Top 5 Holdings (cash excluded)

Name	Weight	Performance	Contribution	Country	Thematic
NOVO NORDISK	4,02%	8,25%	0,33%	Denmark	Social inclusion
SCHNEIDER	3,93%	7,08%	0,26%	France	Energy transition
SAP	3,87%	5,48%	0,20%	Germany	Energy transition
INFINEON TECHNOLOGIES	3,75%	12,23%	0,41%	Germany	Energy transition
SAINT GOBAIN	3,72%	1,89%	0,07%	France	Energy transition
TOTAL	19,30%		1,26%		

Sources: OFLAM & Factset (ICB Classification - Level 2)

3 Best monthly contributions

Name	Weight	Performance	Contribution	Country	Thematic
INFINEON TECHNOLOGIES	3,75%	12,23%	0,41%	Germany	Energy transition
AKER CARBON CAPTURE	2,66%	17,61%	0,40%	Norway	Energy transition
NOVO NORDISK	4,02%	8,25%	0,33%	Denmark	Social inclusion

Sources: OFI AM & Factset (ICB Classification - Level 2)

3 Worst monthly contributions

Name	Weight	Performance	Contribution	Country	Thematic	
ENOGIA	1,20%	-18,28%	-0,27%	France	Energy transition	
AUTOLIV	1,96%	-10,79%	-0,24%	Sweden	Health and well-being	
SVENSKA CELLULOSA	2,33%	-4,79%	-0,12%	Sweden	Protecting natural resources	
Sources: OFI AM & Factset (ICB Classification - Level 2)						

Main movements of the month

Source: OFI AM

Buy /	Increase	
Name	Weight M-1	Weight M
ACCIONA ENERGIAS	0,99%	1,57%

	Sell / Decrease	
Name	Weight M-1	Weight M
ORSTED	2,16%	Sell
SCATEC	0,70%	Sell
BIFFA	3,25%	3,16%
		051414

Source: OFI AM

Asset management strategy

Equity indices once again gained ground in august, with the Stoxx Europe 600 climbing 2.2%. Markets above all welcomed the balanced tone struck at Jackson Hole by the Fed, which is getting ready to taper its asset purchases but has no plans to hike interest rates for the time being. Yet there was no shortage of opportunities to take profits: leading indicators peaked, confirming the deceleration in economic activity, particularly in China, while the spread of the delta variant in Asia, where vaccination rates are low, prompted fresh restrictions that could put more pressure on already strained supply chains. However, the size of stimulus packages - like the Biden administration's infrastructure plan passed by the US Senate in mid-August - and confirmation of even more accommodative monetary policy remain key supports for economic growth in 2022.

Quarterly results season confirmed the scale of the recovery, which analysts had widely underestimated. Cyclical sectors such as industrials, consumer discretionary and those sectors helped by the sharp rise in commodity prices (energy, mining) posted the biggest surprises; against this backdrop, consumer staples were hit doubly hard (as a defensive sector affected by rising input prices).

The ACT4 Positive Economy fund gained 2.87% in the month, outperforming its benchmark, up 2.18%. The main driver of performance was stock selection.

At sector level, the main positive contributors were utilities on the back of strong results from Biffa (waste collection and processing), Orsted and Acciona Energias (in whose IPO the fund participated this summer). In industrials, Aker Carbon Capture racked up a 17% gain following a successful placement to finance its investment requirements. While carbon capture is not a brand new technology, the International Energy Agency considers it one of the top three ways to decarbonise ecosystems. Ramping up industrial carbon capture projects is a prerequisite for this. The number two contributor to performance was the healthcare sector thanks to Novo Nordisk and Lonza (subcontracting of research into and manufacturing of pharmaceutical molecules). Novo Nordisk reported strong results and, above all, announced in August that its Wegovy obesity treatment had been approved in China, where it can be marketed as a weekly formulation from 2022. The newly launched medication has proved successful in other markets and, subject to capacity constraints, could become a blockbuster for the company. The number three contributor to performance was technology, mainly thanks to Infineon (up 12%) in semiconductors, which benefited from mediumterm structural demand, with short-term constraints on supply capacity giving it pricing power.

The main negative contributor was Enogia, which IPO'd the previous month, mainly due to selling by the general public and Telenor's relative poor performance in a defensive sector.

As regards the main changes in the month, we took profits on Biffa in waste management and Novo Nordisk in healthcare and swapped out Scatec Solar and Orsted in order to increase our position in Acciona Energias, which offers growth potential at a more attractive valuation.

Bervi BOUVIER DI NOTA - Arnaud BAUDUIN - Fund manager(s)

This is a non-contractual document provided for information only. This document is intended solely for unitholders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be deemed legally binding. Past performance is no quarantee of future performance and is not constant over time. Stated performance includes all fees with the exception of subscription and redemption fees. Investors in this fund are exposed to risks associated with changes in the value of units or shares in the Fund arising from market fluctuations. As such, the value of an investment may rise or fall, and investors may consequently lose some or all of their initial investment. This document is provided for information purposes only and is not intended to be either legally binding or contractual in nature. The investor acknowledges having received a copy of the prospectus filed with the AMF prior to investing. In spite of the care taken in preparing this document, the management company cannot guarantee that the information it contains is accurate, complete and up to date. The company may not be held liable for any losses incurred by investors who base their investment decisions solely on this document. The information in this document may not be reproduced in full or in part without the prior consent of its author. All requests for further information about the Fund should be directed to OFI Asset Management, 22 rue Vernier, 75017 Paris, France.


CONTACT • Sales Department • 01 40 68 17 17 • contact@ofi-am.fr



Monthly Factsheet - Equities - August 2021











Sources: OFI AM & Factset







Sources: OFI AM & Factse

Statistical Indicators (compared to the benchmark (1) on a 1 year rolling basis)

Beta	Alpha	Tracking Error	Sharpe Ratio (2)	Information Ratio	Frequency of profit	Worst drawdown
0,97	-0,08	6,12%	1,65	-0,79	62,75%	-7,40%
						Source: Factset

Valuation metrics

	PER 2021 (3)	PER 2022 (3)
Fund	20,91	18,79
Benchmark	15,09	14,06

	PBV 2021 (4)	PBV 2022 (4)
Fund	2,62	2,49
Benchmark	1,79	1,70
	-	Sources: Eactset

(1) Benchmark: Stoxx Europe 600 Net Return

(2) Risk free rate: EONIA

(3) PER = Price / Earnings

(4) PBV = Price / Book value

This is a non-contractual document provided for information only. This document is intended solely for unitholders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be deemed legally binding. Past performance is no guarantee of future performance and is not constant over time. Stated performance includes all fees with the exception of subscription and redemption fees. Investors in this fund are exposed to risks associated with changes in the value of units or shares in the Fund arising from market fluctuations. As such, the value of an investment may rise or fall, and investment such provided for information purposes only and is not intended to be either legally binding or contractual in nature. The investor acknowledges having received a copy of the prospectus filed with the AMF prior to investing in this document, the management company cannot guarantee that the information it contains is accurate, complete and up to date. The company may not be held liable for any losses incurred by investors who base their investment decisions solely on this document. The information in this document may not be reproduced in full or in part without the prior consent of its author. All requests for further information about the Fund should be directed to OFI Asset Management, 22 rue Vernier, 75017 Paris, France.


CONTACT • Sales Department • 01 40 68 17 17 • contact@ofi-am.fr



Monthly Factsheet - Equities - August 2021









Novo Nordisk:

Pharmaceutical products (diabetes, obesity).

1- Commitment to sustainable development :

Positive economy theme: Health, safety and well-being

Challenges: > There are more than 425 million people in the world with diabetes - a number that could, according to estimates by the International Diabetes Federation - rise to over 629 million by 2045.

Mission: "Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders."

Intention level: High.

3.4 By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and wellbeing.

32 million people treated for diabetes in 2020

Impact


- 3.b Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines.
- to a policy designed to facilitate access to care. 3.c Substantially increase health financing and the 15,590 healthcare personnel trained at
- recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States.
- end 2020 thanks to the Changing Diabetes in Children programme.


6.3 million people with low income

treated for diabetes at end 2020 thanks

2) Corporate social responsibility:

Novo Nordisk is among those European companies that are "committed" in their response to ESG issues.





(2) SDG: Sustainable Development Goals

(3) SRI: Socially Responsible Investment

This is a non-contractual document provided for information only. This document is intended solely for unlithoiders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be deemed legally binding. Past performance is no guarantee of future performance and is not constant over time. Stated performance includes all fees with the exception of subscription and redemption fees. Investors in this fund are exposed to risks associated with changes in the value of units or shares in the Fund arising from market fluctuations. As such, the value of an investormance includes all fees with the exception of subscription and redemption fees. Investors in this fund are exposed to risks associated with changes in the value of units or shares in the Fund arising from market fluctuations. As such, the value of an investors may consequently lose some or all of their initial investment. This document is provided for information purposes only and is not intended to be either legally binding or contractual in nature. The investor acknowledges having received a copy of the prospectus filed with the AMF prior to investing. In spite of the care taken in preparing this document, the management company cannot guarantee that the information it contains is accurate, complete and up to date. The company may not be held liable for any losses incurred by investors who base their investment decisions sodely on this document. The information in this document may not be reproduced in full or in part without the prior consent of its author. All requests for further information bout the Fund should be directed to OFI Asset Management, 22 rule Vernet, "75017 Pairs, Famour, "75017 Pairs, F



